<DOC>
	<DOCNO>NCT02439632</DOCNO>
	<brief_summary>prulifloxacin inferior levofloxacin hydrochloride treat acute uncomplicated low urinary tract infection chinese</brief_summary>
	<brief_title>A Multi-center , Randomized , Double-blind , Double-dummy Clinical Study Evaluate Safety Efficacy Prulifloxacin Film-coated Tablet Treatment Acute Uncomplicated Lower Urinary Tract Infection With Levofloxacin Hydrochloride Tablet Active Control</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Urinary Tract Infections</mesh_term>
	<mesh_term>Prulifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Levofloxacin</mesh_term>
	<mesh_term>Ofloxacin</mesh_term>
	<criteria>1 . Patients age 18 ~ 65 year old ; 2 . Presence least two follow clinical sign symptom acute uncomplicated low urinary tract infection : dysuria , frequency , urgency suprapubic pain ) onset symptom ≤ 72 hour prior study entry ; 3 . With pyuria : WBC &gt; 10/mm3 unspun urine examine count chamber WBC &gt; 5/hp [ Upper laboratory Norm ( UNL ) ] resuspend sediment centrifuge aliquot urine ( UNL ) ; 4 . Patient willing participate study give signature informed consent form ; 1 . Presence clinical sign symptom suggestive pyelonephritis complicate urinary tract infection ( e.g. , fever &gt; 37.5°C , chill , flank pain ) , factor associate complicated urinary tract infection presence indwell catheter urologic abnormality ; 2 . Women pregnant , nursing plan become pregnant near future ( i.e. , three month ) . Women childbearing potential ( postmenopausal woman must amenorrheic least 12 month consider nonchildbearing potential ) must negative serum pregnancy test screening must willing use acceptable method contraception avoid pregnancy throughout study . Acceptable method contraception include tubal ligation , oral contraceptive , barrier method ( intrauterine device , diaphragm , female condom , male condom ) ; 3 . Three episode acute uncomplicated UTI past 12 month ; 4 . Patients overactive bladder ; 5 . Patients hypersensitive quinolones allergic constitution ; 6 . Administration xanthine , fenbufen , antibiotic antibacterial within two previous week ; 7 . Patients severe condition need combination antibacterial agent corticosteroid study ; 8 . Impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption study drug ( e.g. , ulcerative disease , Inflammatory bowel disease , lactose intolerance , malabsorption syndrome ) 9 . Patients severe liver kidney disease , define serum ALT AST ≥ 2.5 x ULN creatinine ≥ 1.5 x ULN ; 10 . Patients severe heart disease QT prolongation indicate 12lead ECG , arrhythmia acute myocardial ischemia ; 11 . WBC &lt; 3.6 × 109/L neutrophil &lt; 1.8 × 109/L , and/or platelet &lt; 90 × 109/L screening ; 12 . Patients central nervous system disease convulsion history , and/or mental status unable coordinate ; 13 . Patients malignant tumor severe background disease ; 14 . Patients severe immunodeficiency ; 15 . Patients history tendinopathy currently disease , include tendinitis tendon rupture ; 16 . Patients treat experimental drug previous 4 week currently ; 17 . Considered inappropriate study investigator , include patient unable unwilling show compliance protocol .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>